Clinical Reviews in Allergy & Immunology

, Volume 44, Issue 2, pp 109–113 | Cite as

A Cutting Edge Overview: Psoriatic Disease



Psoriasis is a lifelong skin disease, affecting about 2% of the global population. Generalized involvement of the body (erythroderma), extensive pustular lesions, and an associated arthritis known as psoriatic arthritis (PsA) are severe complications of psoriasis. Genetic, immunologic, and environmental factors contribute to its pathogenesis. A complete understanding of the pathogenesis of psoriasis and psoriatic arthritis is lacking. Cytokines, chemokines, adhesion molecules, growth factors like NGF, neuropeptides, and T cell receptors all act in an integrated way to evolve into unique inflammatory and proliferative processes typical of psoriasis and PsA. Management of psoriasis requires exemplary skin care along with careful monitoring of arrays of comorbidities which includes arthritis and coronary artery disease. In many ways, psoriasis can be considered a model autoimmune disease. This statement itself is ironic considering that it was not recognized as immune mediated until relatively recently. Fortunately, the immunobiology has made enormous strides and there are now excellent therapeutic options for patients. In this thematic review, we have attempted to provide summaries of not only basic science and clinical research, but also an overview of future research directions.


Psoriasis Psoriatic arthritis Inflammation Biologics Imaging Epidemiology 


  1. 1.
    Lowes MA, Bowcock AM, Krueger JG (2007) Pathogenesis and therapy of psoriasis. Nature 445:866–873PubMedCrossRefGoogle Scholar
  2. 2.
    Scarpa R, Ayala F, Caporaso N, Olivieri I (2006) Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol 33:210–212PubMedGoogle Scholar
  3. 3.
    Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735–1741PubMedCrossRefGoogle Scholar
  4. 4.
    Kaye JA, Li L, Jick SS (2008) Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 159:895–802PubMedCrossRefGoogle Scholar
  5. 5.
    Stuart PE, Nair RP, Ellinghaus E et al (2010) Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 42:1000–1004PubMedCrossRefGoogle Scholar
  6. 6.
    Nickoloff BJ, Schröder JM, von den Driesch P et al (2000) Is psoriasis a T-cell disease? Exp Dermatol 9:359–375PubMedCrossRefGoogle Scholar
  7. 7.
    Chandran V, Raychaudhuri SP (2010) Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 34:J314–J321PubMedCrossRefGoogle Scholar
  8. 8.
    Nickoloff BJ (2006) Keratinocytes regain momentum as instigators of cutaneous inflammation. Trends Mol Med 12:102–106PubMedCrossRefGoogle Scholar
  9. 9.
    Griffiths CE, Barker JN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370:263–271PubMedCrossRefGoogle Scholar
  10. 10.
    Hertle MD, Kubler MD, Leigh IM, Watt FM (1992) Aberrant integrin expression during epidermal wound healing and in psoriatic epidermis. J Clin Invest 89:1892–1901PubMedCrossRefGoogle Scholar
  11. 11.
    Sa SM, Valdez PA, Wu J et al (2007) The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 178:2229–2240PubMedGoogle Scholar
  12. 12.
    Wolk K, Witte E, Warszawska K et al (2009) The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol 39:3570–3581PubMedCrossRefGoogle Scholar
  13. 13.
    Raychaudhuri SP, Raychaudhuri SK, Genovese MC (2012) L-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 359:419–429PubMedCrossRefGoogle Scholar
  14. 14.
    Raychaudhuri SP, Jiang WY, Raychaudhuri SK (2008) Revisiting the Koebner phenomenon: role of NGF and its receptor system in the pathogenesis of psoriasis. Am J Pathol 172:961–971PubMedCrossRefGoogle Scholar
  15. 15.
    Raychaudhuri SP, Jiang WY, Farber EM, Schall TJ, Ruff MR, Pert CB (1999) Upregulation of RANTES in psoriatic keratinocytes: a possible pathogenic mechanism for psoriasis. Acta Derm Venereol 79:9–11PubMedCrossRefGoogle Scholar
  16. 16.
    Romanowska M, al Yacoub N, Seidel H et al (2008) PPARdelta enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor. J Invest Dermatol 128:110–124PubMedCrossRefGoogle Scholar
  17. 17.
    Széles L, Töröcsik D, Nagy L (2007) PPAR gamma in immunity and inflammation: cell types and diseases. Biochim Biophys Acta 1771:1014–1030PubMedCrossRefGoogle Scholar
  18. 18.
    al Yacoub N, Romanowska M, Krauss S, Schweiger S, Foerster J (2008) PPARdelta is a type 1 IFN target gene and inhibits apoptosis in T cells. J Invest Dermatol 128:1940–1949PubMedCrossRefGoogle Scholar
  19. 19.
    Sagoo GS, Tazi-Ahnini R, Barker JW et al (2004) Meta-analysis of genome-wide studies of psoriasis susceptibility reveals linkage to chromosomes 6p21 and 4q28-q31 in Caucasian and Chinese Hans population. J Invest Dermatol 122:1401–1405PubMedCrossRefGoogle Scholar
  20. 20.
    Burden AD, Javed S, Bailey M, Hodgins M, Connor M, Tillman D (1998) Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p. J Invest Dermatol 110:958–960PubMedCrossRefGoogle Scholar
  21. 21.
    Veal CD, Clough RL, Barber RC et al (2001) Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci. J Med Genet 38:7–13PubMedCrossRefGoogle Scholar
  22. 22.
    Capon F, Semprini S, Chimenti S et al (2001) Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21. J Invest Dermatol 116:728–730PubMedCrossRefGoogle Scholar
  23. 23.
    Nair RP, Duffin KC, Helms C et al (2009) Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 41:199–204PubMedCrossRefGoogle Scholar
  24. 24.
    Zhang XJ, Huang W, Yang S et al (2009) Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet 41:205–210PubMedCrossRefGoogle Scholar
  25. 25.
    Campalani E, Allen MH, Fairhurst D et al (2006) Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol 154:345–352PubMedCrossRefGoogle Scholar
  26. 26.
    Gottlieb AB, Lebwohl M, Shirin S et al (2000) Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol 43:595–504PubMedCrossRefGoogle Scholar
  27. 27.
    Wrone-Smith T, Nickoloff BJ (1996) Dermal injection of immunocytes induces psoriasis. J Clin Invest 98:1878–1887PubMedCrossRefGoogle Scholar
  28. 28.
    Eyerich S, Eyerich K, Pennino D et al (2009) Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 119:3573–3585PubMedGoogle Scholar
  29. 29.
    Caruso R, Botti E, Sarra M et al (2009) Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 15:1013–1015PubMedCrossRefGoogle Scholar
  30. 30.
    Di Cesare A, Di Meglio P, Nestle FO (2009) The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 129:1339–1350PubMedCrossRefGoogle Scholar
  31. 31.
    Shibata S, Tada Y, Kanda N et al (2010) Possible roles of IL-27 in the pathogenesis of psoriasis. J Invest Dermatol 130:1034–1039PubMedCrossRefGoogle Scholar
  32. 32.
    Lowes MA, Chamian F, Abello MV et al (2005) Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci 102:19057–19062PubMedCrossRefGoogle Scholar
  33. 33.
    Wang H, Peters T, Kess D et al (2006) Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest 116:2105–2114PubMedCrossRefGoogle Scholar
  34. 34.
    Braverman IM, Yen A (1977) Ultrastructure of the capillary loops in the dermal papillae of psoriasis. J Invest Dermatol 68:53–60PubMedCrossRefGoogle Scholar
  35. 35.
    Reece RJ, Canete JD, Parsons WJ, Emery P, Veale DJ (1999) Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis Rheum 42:1481–1484PubMedCrossRefGoogle Scholar
  36. 36.
    Creamer D, Sullivan D, Bicknell R, Barker J (2002) Angiogenesis in psoriasis. Angiogenesis 5:231–236PubMedCrossRefGoogle Scholar
  37. 37.
    Libby P, Paul M, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135–1143PubMedCrossRefGoogle Scholar
  38. 38.
    Zaman AG, Helft G, Worthley SG, Badimon JJ (2000) The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 149:251–266PubMedCrossRefGoogle Scholar
  39. 39.
    Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaudhuri SP (2010) Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord 8:331–334PubMedCrossRefGoogle Scholar
  40. 40.
    Bizzaro N, Tozzoli R, Shoenfeld Y (2007) Are we at a stage to predict autoimmune rheumatic diseases? Arthritis Rheum 56:1736–1744PubMedCrossRefGoogle Scholar
  41. 41.
    Hershko AY, Naparstek Y (2006) Autoimmunity in the era of genomics and proteomics. Autoimmun Rev 5:230–233PubMedCrossRefGoogle Scholar
  42. 42.
    Hoffmann MH, Trembleau S, Muller S, Steiner G (2010) Nucleic acid-associated autoantigens: pathogenic involvement and therapeutic potential. J Autoimmun 34:J178–J206PubMedCrossRefGoogle Scholar
  43. 43.
    Mackay IR (2010) Travels and travails of autoimmunity: a historical journey from discovery to rediscovery. Autoimmun Rev 9:A251–A258PubMedCrossRefGoogle Scholar
  44. 44.
    Martin PI, Malizia AI, Rewald E (2008) A propos time and autoimmunity. Clin Rev Allergy Immunol 34:380–384PubMedCrossRefGoogle Scholar
  45. 45.
    Maverakis E, Miyamura Y, Bowen MP, Correa G, Ono Y, Goodarzi H (2010) Light, including ultraviolet. J Autoimmun 34:J247–J257PubMedCrossRefGoogle Scholar
  46. 46.
    Chen M, Daha MR, Kallenberg CG (2010) The complement system in systemic autoimmune disease. J Autoimmun 34:J276–J286PubMedCrossRefGoogle Scholar
  47. 47.
    Selmi C (2010) The worldwide gradient of autoimmune conditions. Autoimmun Rev 9:A247–A250PubMedCrossRefGoogle Scholar
  48. 48.
    Youinou P, Pers JO, Gershwin ME, Shoenfeld Y (2010) Geo-epidemiology and autoimmunity. J Autoimmun 34:J163–J167PubMedCrossRefGoogle Scholar
  49. 49.
    Selmi C, Tsuneyama K (2010) Nutrition, geoepidemiology, and autoimmunity. Autoimmun Rev 9:A267–A270PubMedCrossRefGoogle Scholar
  50. 50.
    Shapira Y, Agmon-Levin N, Shoenfeld Y (2010) Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 34:J168–J177PubMedCrossRefGoogle Scholar
  51. 51.
    Shoenfeld Y, Selmi C, Zimlichman E, Gershwin ME (2008) The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmun 31:325–330PubMedCrossRefGoogle Scholar
  52. 52.
    Stojanovich L (2010) Stress and autoimmunity. Autoimmun Rev 9:A271–A276PubMedCrossRefGoogle Scholar
  53. 53.
    Tobon GJ, Youinou P, Saraux A (2010) The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. Autoimmun Rev 9:A288–A292PubMedCrossRefGoogle Scholar
  54. 54.
    Chen M, Kallenberg CG (2010) The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun Rev 9:A293–A298PubMedCrossRefGoogle Scholar
  55. 55.
    Ehrenfeld M (2010) Geoepidemiology: the environment and spondyloarthropathies. Autoimmun Rev 9:A325–A329PubMedCrossRefGoogle Scholar
  56. 56.
    Leung PS, Shu SA, Kenny TP, Wu PY, Tao MH (2010) Development and validation of gene therapies in autoimmune diseases: epidemiology to animal models. Autoimmun Rev 9:A400–A405PubMedCrossRefGoogle Scholar
  57. 57.
    Round JL, O’Connell RM, Mazmanian SK (2010) Coordination of tolerogenic immune responses by the commensal microbiota. J Autoimmun 34:J220–J225PubMedCrossRefGoogle Scholar
  58. 58.
    Sands J, Tuscano JM (2010) Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders. Autoimmun Rev 9:A335–A341PubMedCrossRefGoogle Scholar
  59. 59.
    Lleo A, Invernizzi P, Gao B, Podda M, Gershwin ME (2010) Definition of human autoimmunity—autoantibodies versus autoimmune disease. Autoimmun Rev 9:A259–A266PubMedCrossRefGoogle Scholar
  60. 60.
    Logan I, Bowlus CL (2010) The geoepidemiology of autoimmune intestinal diseases. Autoimmun Rev 9:A372–A378PubMedCrossRefGoogle Scholar
  61. 61.
    Meyer N, Misery L (2010) Geoepidemiologic considerations of auto-immune pemphigus. Autoimmun Rev 9:A379–A382PubMedCrossRefGoogle Scholar
  62. 62.
    Powell JJ, Faria N, Thomas-McKay E, Pele LC (2010) Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. J Autoimmun 34:J226–J233PubMedCrossRefGoogle Scholar
  63. 63.
    Borchers AT, Naguwa SM, Keen CL, Gershwin ME (2010) The implications of autoimmunity and pregnancy. J Autoimmun 34:J287–J299PubMedCrossRefGoogle Scholar
  64. 64.
    Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME (2010) The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 9:A277–A287PubMedCrossRefGoogle Scholar
  65. 65.
    Borchers AT, Uibo R, Gershwin ME (2010) The geoepidemiology of type 1 diabetes. Autoimmun Rev 9:A355–A365PubMedCrossRefGoogle Scholar
  66. 66.
    Brooks WH, Le Dantec C, Pers JO, Youinou P, Renaudineau Y (2010) Epigenetics and autoimmunity. J Autoimmun 34:J207–J219PubMedCrossRefGoogle Scholar
  67. 67.
    Chang C (2010) The immune effects of naturally occurring and synthetic nanoparticles. J Autoimmun 34:J234–J246PubMedCrossRefGoogle Scholar
  68. 68.
    Arnson Y, Shoenfeld Y, Amital H (2010) Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 34:J258–J265PubMedCrossRefGoogle Scholar
  69. 69.
    Langham S, Langham J, Goertz HP, Ratcliffe M (2011) Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: a systemic and critical review. BMC Med Res Methodol 11:32PubMedCrossRefGoogle Scholar
  70. 70.
    Slutsky JB, Clark RA, Remedios AA, Klein PA (2010) An evidence-based review of the efficacy of coal tar preparations in the treatment of psoriasis and atopic dermatitis. J Drugs Dermatol 9:1258–1264PubMedGoogle Scholar
  71. 71.
    O’Neill JL, Feldman SR (2010) Vitamine D analogue-based therapies for psoriasis. Drugs Today (Barc) 46:351–360Google Scholar
  72. 72.
    Seminara NM, Gelfand JM (2010) Assessing long-term drug safety: lessons (re) learned from raptiva. Semin Cutan Med Surg 29:16–19PubMedCrossRefGoogle Scholar
  73. 73.
    Baraliakos X, Braun J (2010) Anti-TNF-alpha therapy with infliximab in spondyloarthritides. Expert Rev Clin Immunol 6:9–19PubMedCrossRefGoogle Scholar
  74. 74.
    Borchers AT, Leibushor N, Cheema GS, Naguwa SM, Gershwin ME (2011) Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases. J Autoimmun 37:273–288PubMedCrossRefGoogle Scholar
  75. 75.
    Piconese S, Costanza M, Tripodo C, Sangaletti S, Musio S, Pittoni P, Poilani PL, Burocchi A, Passafaro AL, Gorzanelli A, Vitali C, Chiodoni C, Barnaba V, Pedotti R, Colombo MP (2011) The matricellular protein SPARC supports follicular dendritic cell networking toward Th17 responses. J Autoimmun 37:300–310PubMedCrossRefGoogle Scholar
  76. 76.
    Dagur PK, Biancotto A, Wei L, Sen HN, Yao M, Strober W, Nussenblatt RB, Philip McCoy J Jr (2011) MCAM-expressing CD4(+) T cells in peripheral blood secrete IL-17A and are significantly elevated in inflammatory autoimmune diseases. J Autoimmun 37:319–327PubMedCrossRefGoogle Scholar
  77. 77.
    Kaminski S, Hermann-Kleiter N, Meisel M, Thuille N, Cronin S, Hara H, Fresser F, Penninger JM, Baier G (2011) Coronin 1A is an essential regulator of the TGFβ receptor/SMAD3 signaling pathway in Th17 CD4(+) T cells. J Autoimmun 37:198–208PubMedCrossRefGoogle Scholar
  78. 78.
    Wang YL, Chou FC, Chen SJ, Lin SH, Chang DM, Sytwu HK (2011) Targeting pre-ligand assembly domain of TNFR1 ameliorates autoimmune diseases—an unrevealed role in downregulation of Th17 cells. J Autoimmun 37:160–170PubMedCrossRefGoogle Scholar
  79. 79.
    Baugh M, Black D, Westwood P, Kinghorn E et al (2011) Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity. J Autoimmun 36:201–209PubMedCrossRefGoogle Scholar
  80. 80.
    Hickman-Brecks CL, Racz JL, Meyer DM, LaBranche TP, Allen PM (2011) Th17 cells can provide B cell help in autoantibody induced arthritis. J Autoimmun 36:65–75PubMedCrossRefGoogle Scholar
  81. 81.
    Oo YH, Adams DH (2010) The role of chemokines in the recruitment of lymphocytes to the liver. J Autoimmun 34:45–54PubMedCrossRefGoogle Scholar
  82. 82.
    Reich A, Szepietowski JC (2011) Health-related quality of life in patients with nail disorders. Am J Clin Dermatol 12:313–320PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of MedicineVA Sacramento Medical CentreMatherUSA
  2. 2.Division of Rheumatology, Allergy and Clinical ImmunologyUniversity of California Davis, School of MedicineSacramentoUSA

Personalised recommendations